| Ytd | -22.46% | |
| 1y | 7.99% |
| Open | 12.60 | Prev Close | 12.36 | Low | 12.38 | High | 12.86 | Mkt Cap | 570.34M |
| Vol | 581.16K | Avg Vol | 838.40K | EPS | 0.52 | P/E | 23.90 | Forward P/E | 17.18 |
| Beta | 2.36 | Short Ratio | 23.15 | Inst. Own | 112.62% | Dividend | 0.04 | Div Yield | 0.24 |
| Ex Div Date | 11-04 | Earning | 10-28 | 50-d Avg | 11.55 | 200-d Avg | 15.10 | 1yr Est | 19.33 |
BlackRock Inc. acquired a new stake in Core Laboratories Inc. (NYSE: CLB) during the second quarter,
Core Laboratories (CLB) reported earnings 30 days ago. What's next for the stock?
Advisors Capital Management LLC purchased a new stake in Core Laboratories Inc. (NYSE: CLB) during t
On June 30, 2026, John Rogers (Trades, Portfolio), founder of Ariel Investment, LLC, increased the f
Investors looking for stocks in the Oil and Gas - Field Services sector might want to consider eithe
Core Laboratories stock looks cheaper after a 47.1% six-month selloff, but falling earnings and geop
CLB's Q2 earnings top estimates despite lower revenues and profit as Production Enhancement strength
Core Laboratories NYSE: CLB reported second-quarter 2026 revenue of $124.6 million, up more than 2%
Core Laboratories Inc. (CLB) Q2 2026 Earnings Call Transcript
Core Laboratories (CLB) came out with quarterly earnings of $0.11 per share, beating the Zacks Conse
Core Laboratories (NYSE:CLB) reported quarterly earnings of $0.11 per share which beat the analyst c
REVENUE OF $ 124.6 MILLION, UP 2% SEQUENTIALLY AND DOWN 4% YEAR-OVER-YEAR OPERATING INCOME OF $ 9.2
Core Laboratories (NYSE:CLB) is looking for Q3 GAAP EPS of $0.12-$0.20 vs $0.16 analyst estimate. se
The Ariel Small/Mid Cap Value Composite rose +15.08% gross of fees (+14.95% net of fees) in the quar
CLB's Q2 may reflect resilient international activity and tariff insulation, but weaker reservoir de
Core Laboratories (CLB) doesn't possess the right combination of the two key ingredients for a likel
CLB struggles with ongoing headwinds from lower completion activity, operational disruptions, inflat
HOUSTON, June 30, 2026 /PRNewswire/ -- Core Laboratories (NYSE: "CLB") will host its second quarter
https://www.spglobal.com/spdji/en/documents/indexnews/announcements/20260626-1484136/1484136_spgi-se
CLB faces persistent geopolitical uncertainty, weaker laboratory activity, cost inflation and delaye
Arista Networks (NYSE: ANET), a leader in modern AI fabric networking, today announced the Arista [u
Core Laboratories (CLB) reported earnings 30 days ago. What's next for the stock?
Investors need to pay close attention to CLB stock based on the movements in the options market late
Opportunity to buy undervalued energy stocks as RSI shows oversold levels. NCS Multistage, Core Labo
Core Laboratories (NYSE:CLB) is looking for Q2 GAAP EPS of $0.06-$0.12 vs $0.09 analyst estimate. se
Core Laboratories (NYSE:CLB) reported quarterly earnings of $0.06 per share which missed the analyst
Core Laboratories (NYSE:CLB) is looking for Q1 Adj EPS of $0.05-$0.07 vs $0.14 analyst estimate. Low
Core Laboratories (NYSE:CLB) is looking for Q1 GAAP EPS of $0.11-$0.15 vs $0.15 analyst estimate. se
Core Laboratories (NYSE:CLB) reported quarterly earnings of $0.21 per share which beat the analyst c
Stifel analyst Stephen Gengaro maintains Core Laboratories (NYSE:CLB) with a Hold and lowers the
Citigroup analyst Scott Gruber maintains Core Laboratories (NYSE:CLB) with a Neutral and lowers t
Core Laboratories (NYSE:CLB) is looking for Q2 GAAP EPS of $0.17-$0.21 vs $0.24 analyst estimate. se
Core Laboratories (NYSE:CLB) reported quarterly earnings of $0.14 per share which missed the analyst
Stifel analyst Stephen Gengaro maintains Core Laboratories (NYSE:CLB) with a Hold and lowers the
Citigroup analyst Scott Gruber upgrades Core Laboratories (NYSE:CLB) from Sell to Neutral and rai
Citigroup analyst Scott Gruber maintains Core Laboratories (NYSE:CLB) with a Sell and raises the
Core Laboratories (NYSE:CLB) reported quarterly earnings of $0.22 per share which met the analyst co